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Background: Hepatitis B virus (HBV) infection has been believed as a major cause of hepatocellular carcinoma
(HCC) for a long time, however, the evidences of which are mostly from clinical and epidemiological investigations
while there is no evidence from animal experiments. Tree shrew (Tupaia) is a small animal closely related to
primates evolutionarily, with about 8 years of lifespan. Our previous study proved that tree shrews can be chronically
HBV-infected after being inoculated neonatally with HBV. The present study reports the further results from the
longer-term observation of these animals.
Methods: Neonatal tree shrews were inoculated with sera from HBV-infected patient or tree shrew. Their serum
samples and liver biopsies were collected periodically for detection of HBV markers as well as for histopathological and
immunohistochemical examinations. Group A consisted of six tree shrews with chronic HBV-infection, and group B
consisted of nine tree shrews without chronic HBV infection.
Results: Periodical examinations on serum and liver biopsies of the animals in group A showed the progress of HBV
infection, and two cases of HCC occurred at their late stage of life. The courses of HBV infection and the hepatic
histopathological and immunohistochemical changes in the tree shrews were similar to those in humans. In contrast,
neither HCC nor obvious hepatitis histopathological change was found among the tree shrews in group B.
Conclusions: The course of HBV infection and the features of HCC discovered in tree shrews are similar to those of
chronically HBV-infected humans. The tree shrew model might be used to investigate the underlying mechanisms
favoring susceptibility for chronic HBV infection and disease progression.
Keywords: Tree shrew (Tupaia), Hepatitis B virus, Hepatocellular carcinoma, Animal modelBackground
Etiologically, the intimate relationship between human
hepatitis B virus (HBV) infection and hepatocellular car-
cinoma (HCC), one of the most aggressive malignancies
worldwide, is well recognized. The evidences of which,
however, are mostly from clinical and epidemiological in-
vestigations [1-3] but not from systematic experimental
studies. The main obstacle herein is the lack of suitable* Correspondence: liyuangx@aliyun.com
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unless otherwise stated.animal models, because the common laboratory animals
are unsusceptible to HBV infection except chimpanzees.
The tree shrew (Tupaia) is a small animal classified
currently in the order Scandentia and the superorder
Euarchonta, with about 8 years lifespan. Compared to
rats, mice, woodchucks and other laboratory animals,
tree shrews show greater similarities with humans in
many aspects such as genomic and immunological char-
acteristics. Tree shrews, therefore, have been used in
biomedical research for decades, especially in studies re-
lated to certain human viral diseases in recent years
[4-9]. Since the early 1980s, studies have shown that tree
shrews can be infected with HBV in vitro and probably
in vivo [10-12], and HCC can be experimentally inducedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bination with HBV [13-15]. However, only one case of
HBV alone-associated HCC has been reported so far,
which was discovered in a tree shrew that had been ori-
ginally captured in the wild during adulthood and then
inoculated with HBV [14].
By study on a colony of laboratory-reared tree shrews
that were inoculated with HBV at birth, we reported pre-
viously that six tree shrews were chronically HBV-
infected, according to the criterion that HBV infection
lasts longer than 48 weeks after inoculation [16]. Subse-
quently, we described that the histopathological changes
in the liver of these persistently HBV-infected tree shrews
were quite similar to those found in humans [17]. By
continuous observation, HCC were discovered recently in
two of the six chronically HBV-infected tree shrews but
none among the nine controls that were confirmed as
non-chronic HBV infection. This study investigated the
progress from chronic HBV infection to the development
of HCC in tree shrews.
Results
General information of the animals
All tree shrews observed in this study were from our
previous investigations in which they were all inoculated
with HBV at birth [16]. Group A consisted of six treeTable 1 General information of the animals in group A and B
Group Animal Sex Period of observa






Mean ± SD 245.67 ± 90.86c









Mean ± SD 249.11 ± 33.44c
aPeriod of observation, equals to the age of animal because all animals in this study
bNatural death, the death was without clear cause.
cThe difference of observation period between two groups was not statistically sign
*Reference: Ruan P, Yang C, Su J, Cao J, Ou C, Luo C, Tang Y, Wang Q, Yang F, Shi J
chinensis) persistently infected with hepatitis B virus. Virol J 2013, 10:333.shrews that were chronically HBV-infected, while group B
consisted of nine tree shrews that were confirmed as non-
chronically HBV-infected. The average periods of observa-
tion on the animals in group A and B were 245.7 ± 90.9
and 249.1 ± 33.4 weeks after HBV-inoculation, respect-
ively, and the difference of which was not statistically
significant. Table 1 shows the general information of the
animals in the two groups.
Processes of HBV infection
Figure 1 displays the time course of the HBV-infection
markers in all six tree shrews of group A. Generally, the
elevated levels of HBsAg in serum as well as HBV DNA
in serum and in liver appeared shortly after HBV inocu-
lation, followed by gradual increase with intermittent
fluctuations. Typically, the serum HBeAg and HBcAb
were positive at almost all time points in some animals
such as 98–2 and 121–1, while HBsAb and HBeAb remained
negative throughout.
On the other hand, as shown in Table 2, the HBV-
infection markers of all tree shrews in group B indicate
that none of them were chronically HBV-infected.
Occurrence of HCC
At the end of this study, two cases of liver tumor were
found in tree shrews of group A, namely 98–2 and 121–1,tion (week)a Condition at the end of studyb
Sacrificed for a suspected liver tumor which was
confirmed as liver cell dysplasia microscopically*.
Natural death.
Sacrificed because of HCC.












were inoculated at birth and observed since then.
ificant (P = 0.607, Wilcoxon W = 67).
, et al.: Histopathological changes in the liver of tree shrew (Tupaia belangeri
Figure 1 Progress of HBV infection in tree shrews of group A. The number on the top of each panel refers the name of animal. HBV DNA in
serum and liver samples was detected by FQ-PCR. The result of HBV DNA detection was expressed as IU/ml in serum and as IU/μg liver DNA in
liver. Serum HBsAg was detected by TRFIA and the result was expressed as ng/ml. Serum HBsAb, HBeAg, HBeAb and HBcAb were detected by
ELISA and the results were expressed as “+” (positive), “-” (negative) or “±” (between positive and negative).
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ively). Their other organs, including heart, lung, spleen,
kidney, stomach and intestine, were basically normal
by both gross and microscopic examinations. No tumor
was found in the tree shrews of group B. The general
information of the two cases of liver tumor is listed in
Table 3.
The overall appearance and the cross-section’s view
of the two liver tumors are shown in Figure 2. Generally,
both tumors were single nodule and oval in shape, with
uneven and mottled surface. The cross-sections of the
nodules exhibited uneven color, mostly grayish white or
dark red, and the parenchyma of the tumors were brittle.
HBsAg and HBcAg Immunohistochemical staining on
the two cases of liver tumor showed sporadically or dif-
fusely distributed HBsAg- and HBcAg-positive hepatocytes
in tumor-surrounding (peri-tumor) tissues, respectively,
while fewer HBsAg-positive cells and none HBcAg-
positive cells in tumor tissues (Figure 3A and B). Long-
term observation on the liver biopsies from all the animals
in group A reveals that, generally, HBsAg- and HBcAg-
positive hepatocytes appeared early and increased slowly
over time (Figure 3C and D). No HBsAg- or HBcAg-
positive hepatocyte was found in any animals of group B
at any time point during the years of observation (Figure 3E
and F).Under microscope, the tumor cells showed typical
hepatocyte-like features such as round, cuboidal or polyg-
onal in shape. Some cells exhibited marked atypia and
pleomorphism with enlarged nuclei and darker chromatin,
as well as increased ratio of nucleus to cytoplasm. Numer-
ous multinucleated cells presented, and mitotic figure and
abnormal mitoses were frequently observed (Figure 4A).
Some of the tumor cells showed transparent cytoplasm,
which were proved to be rich in glycogen by periodic acid-
Schiff (PAS) staining. The tumor cells arranged in solid,
trabecular or pseudoglandular patterns (Figure 4B). Invasive
growth, necrosis and hemorrhage presented in some areas
of the tumors. The peri-tumor tissues exhibited chronic
hepatitis changes, some with dysplastic nodules, but no sig-
nificant fibrosis or cirrhosis was observed.
Figure 5 shows part of the results of immunohisto-
chemical study that helped to determine the nature of
the two liver tumors. Strong positive HepPar-1 cells
were observed in both tumor and normal liver tissues
(Figure 5A and B). CD31-positive sinusoidal endothelial
cells, arranged in special strip-like or branch-like patterns,
were found in tumor tissues (Figure 5C). The hepatic
sinusoidal endothelial cells in non-tumor tissues were
generally CD31-negative, here only blood vessels in portal
tracts and/or a fewer sinusoidal spaces near portal tracts
were positive (Figure 5D).




6 12 24 36 48 ~150** ~250**
108-4 HBV DNA /# - - ± ± - -
HBsAg / / / / - - -
HBsAb / / / / + ± -
HBeAg / / / / - - -
HBeAb / / / / - - -
HBcAb / / / / - - -
117 HBV DNA 1.10 × 103 - ± - - 1.92 × 103 -
HBsAg ± ± - - - - -
HBsAb + + - ± - + +
HBeAg - - - - - - -
HBeAb - - - - - - -
HBcAb - - - - - + -
122-2 HBV DNA - ± - - - - -
HBsAg ± ± - - - - -
HBsAb + + ± ± - + +
HBeAg - - - - - - -
HBeAb - - - - - - +
HBcAb - - - - - - +
131-3 HBV DNA ± ± - - ± - -
HBsAg - - - - - - -
HBsAb + + ± ± - - -
HBeAg - - - - - - -
HBeAb - + ± ± - - -
HBcAb - + - ± - - +
133-2 HBV DNA 1.24 × 103 3.01 × 103 ± 3.5 × 103 - - -
HBsAg - - - - - - -
HBsAb + + ± - - - -
HBeAg - - - - - - -
HBeAb + + ± - - - -
HBcAb - + - - - - -
133-3 HBV DNA ± 1.04 × 103 ± 1.12 × 104 1.46 × 104 - -
HBsAg - - - - - - -
HBsAb - ± ± - - - -
HBeAg - - - - - - -
HBeAb - - + + + - -
HBcAb - + + + + - -
136-2 HBV DNA - - - - - - -
HBsAg - - - - - - -
HBsAb - ± + + ± + ±
HBeAg - - - - - - -
HBeAb - + - - + - -
HBcAb - + - + + - -
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Table 2 Serum HBV-infection markers in the tree shrews of group B (Continued)
137-2 HBV DNA ± - - ± ± - -
HBsAg - - - - - -
HBsAb - - + - + + +
HBeAg - - - + - - -
HBeAb - - + - - - -
HBcAb - - - - - - -
140-3 HBV DNA 1.31 × 103 ± - / - - -
HBsAg - - - / - - -
HBsAb - + - / - ± -
HBeAg - - - / - - -
HBeAb - - - / - - +
HBcAb + + - / - - -
*HBV DNA in serum was detected by FQ-PCR, the results were expressed as values of IU/ml (positive), “-” (values < 0.5 × 102 IU/ml) or “±” (values between 0.5 × 102-1.0 ×
103 IU/ml). Serum HBsAg, HBsAb, HBeAg, HBeAb and HBcAb were detected by ELISA, the results were expressed as “+” (positive), “-” (negative) or “±” (between positive
and negative).
**“~150” means around 150 weeks. “~250” means around 250 weeks, the last time of detection.
#Not tested at this time point.
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two liver tumors were moderately to poorly differenti-
ated HCC. Besides, as our pervious description [17], the
liver biopsies collected from the two HCC-carried tree
shrews before the appearance of HCC showed slowly ag-
gravated changes of hepatitis, such as piecemeal necrosis
and periportal inflammation.
Progress of hepatocyte proliferation during HCC
development identified by Ki67 immunohistochemistry
As shown in Figure 6, the density of Ki67-positive cells
in the HCC tissue was much higher than that in the
compared tissues such as peri-HCC tissues, liver biop-
sies collected from the animals in group A prior to HCC
occurrence (pre-HCC), and the liver biopsies collected
from the animals in group B long after HBV-inoculation.
The proportion (%) of Ki67-positive cells in HCC tissues
was significantly higher than that in the liver biopsies of
group B (Table 4).
Discussion
The data presented above indicate that HCC can
develop in the tree shrews with chronic HBV infection.Table 3 General information of the two cases of liver tumor
Information Animal
98-2
Body weight (g) 142.0
liver weight (g) 13.6
Size and location of the liver tumor Single nodule sized 2.5×2×2 cm
bottom of the right posterior lob
capsule but with a visible bound
on its cross section.Their HBV-related serological, hepatic histopathological
and Immunohistochemical changes are similar to those
of HBV-infected humans. These animals were nursed
artificially in our lab from birth, without any other treat-
ment except inoculation with HBV at their neonatal
period and then periodical collection of blood sample
and liver biopsy throughout their lifetime. As no HCC
was found in the nine controls that were not chronically
HBV-infected during several years of observation, as well
as no spontaneous HCC in tree shrew has ever been
found in our lab or reported by any others up to now,
the conclusion might be drawn therefore, that the HCCs
presented in this study were likely induced by HBV.
The histopathological changes observed in the two
tree shrews’ HCC and peri-HCC tissues are similar to
those observed commonly in human HCC. Furthermore,
the immunohistochemical results of HepPar-1, CD31
and Ki67 suggest tree shrew’s HCC possesses certain
phenotypes that are similar to that of human HCC.
These markers had the supplementary diagnostic value
for human HCC in clinical pathology. For examples,
HepPar-1 is helpful in determining whether the tumor
cells are hepatocyte-derived; CD31 is an angiogenesis-121-1
117.7
21.2
, located at the
e, without
ary zone
Single nodule without obvious edge, sized about
3×3×2.5 cm, occupied and merged most parts of
the left, middle and right posterior lobes. A cyst
located on the surface of the tumor, sized
2.5×2×1.8 cm, containing yellow clear liquor.
Figure 2 Gross images of liver tumors. The figures show the overall appearance and cross sections of the liver tumors developed in tree
shrews 98–2 (left) and 121–1 (right) respectively. Generally, both tumors were solitary nodule and oval in shape, with uneven and mottled
surface. The textures of the tumors were brittle. The cross sections of the nodules were nonuniform in color, mostly grayish white (lower left) or
dark red (lower right). The three arrows in each picture point the edge of the tumor. The scale in each picture indicates tumor size.
Yang et al. Virology Journal  (2015) 12:26 Page 6 of 10related marker for identifying cancer tissue from normal
tissue, and Ki67 (PCNA) is a marker indicating cell pro-
liferation [18-20]. Particularly, Ki67 was found positively
related to HCC progression in human and mice [20,21],
while our result of Ki67 staining showed the same ten-
dency during the development of tree shrews’ HCC.
Meanwhile, our result showed that the distributions of
HBsAg- and HBcAg-positive hepatocytes were more
often in peri–HCC tissues of tree shrews but much less
in HCC tissues themselves, which are similar again to
those observed commonly in human HBV-related HCC
[22]. All of these evidences, as well as the history of
HBV infection, consistently support that the two liver
tumors of tree shrews are analogous to the HBV-related
HCC in human being.
Even though all the tree shrews in this study were
HBV-inoculated neonatally and then nursed artificially,
their outcomes were notably various. For instance, ex-
cept the two tree shrews in group A (97–1 and 122–1)
died earlier, the remaining four in this group were ob-
served for long time. While among these four, the two
animals (98–2 and 121–1) that showed typical and pro-
nounced serological changes, i.e., consistently positive
of HBsAg, HBeAg and HBcAb, as well as elevated
levels of HBV DNA, finally developed HCC in their late
stage of life. While in the other two with relatively
moderate serological changes, one (90–1) showed mild
hepatic fibrosis and obvious dysplastic hepatocytes
which is generally believed as precancerous change ofHCC [17]; the last (123–3) is still survival, without his-
tologically confirmed HCC yet, but suspected liver nod-
ules were detected by B-ultrasound recently (data not
shown). Whereas, the tree shrews in group B were not
chronically infected after HBV inoculation, based on
the long-term observation of their serum samples and
liver biopsies. This phenomenon, similar to the situ-
ation observed in HBV-infected humans, indicates that
the outcome after HBV infection is not only deter-
mined by HBV but also by some of host’s factors.
The present study proves preliminarily that HBV alone
can induce HCC, but the carcinogenic ability of HBV is
relatively weak, because it requires a much longer period
of time to induce HCC when comparing to AFB1, an-
other important etiologic factor for HCC in southern
China and Africa. According to the reports from our lab
and others [13,14,23], the period of time for AFB1 alone
to induce HCC in tree shrews was much shorter: no
more than 172 weeks. Besides, the HBV genotype B used
in this study [16] might be partially responsible for the
long induction time, since the HBV genotype C and sub-
genotype Ce are reported to have higher risk for HCC
[24,25]. Meanwhile, it is worthwhile to note that the tree
shrew 121–1, one of the HCC-carriers in this study, was
inoculated with serum from another tree shrew (90–1)
who had been previously diagnosed as having chronic
HBV infection. Compared with another HCC-carrier 98–1
who was inoculated with serum from a HBV-infected pa-
tient, the period of HCC development in tree shrew 121–1
Figure 3 HBsAg and HBcAg immunohistochemistry. A. HBsAg in liver tumor and tumor-surrounding tissues. HBsAg-positive hepatocytes
distributed sporadically or diffusely in the tumor-surrounding tissue (left area). On the contrary, HBsAg-positive cells were rarely seen inside the tumor
(right area). Tumor and tumor-surrounding tissues of 98–2, immunohistochemical staining for HBsAg, 100×. B. HBcAg in liver tumor and tumor-
surrounding tissues. HBcAg-positive hepatocytes distributed sporadically or diffusely in the tumor-surrounding tissue (right area). On the contrary, the
HBcAg-positive cell was not observed inside the tumor (left area). Tumor and tumor-surrounding tissues of 121–1, immunohistochemical staining for
HBcAg, 200×. C. HBsAg in biopsies collected before occurrence of liver tumor. HBsAg appeared in the cytoplasm of some hepatocytes. A liver biopsy
specimen of 121–1 at the 221st week after inoculation, immunohistochemical staining for HBsAg, 200×. D. HBcAg in biopsies collected before
occurrence of liver tumor. HBcAg appeared in the nucleus of some hepatocytes. A liver biopsy specimen of 121–1 at the 221st week after inoculation,
immunohistochemical staining for HBcAg, 200×. E. HBsAg in the biopsies of animals in group B. No HBsAg-positive hepatocyte was found in the liver
biopsies from animals in group B. A liver biopsy specimen of 108–4 at the 311th week after inoculation, immunohistochemical staining for HBsAg,
100×. F. HBcAg in the biopsies of animals in group B. No HBcAg-positive hepatocyte was found in the liver biopsies from animals in group B. A liver
biopsy specimen of 108–4 at the 311th week after inoculation, immunohistochemical staining for HBcAg, 100×.
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bigger. This might imply that the HBV adapted in vivo of
tree shrew own more potent to induce HCC in the same
species. However, the conclusions on these points are lim-
ited by the small sample size of this study.Figure 4 Histological images of the liver tumors. A. Neoplastic cells. The n
cells (arrow) and abnormal mitoses (insert) were evident. Tumor tissue of 98–2
patterns. Three morphological patterns were found in tumors. The solid patte
and lack of sinusoids (two upper panels). The trabecular pattern was the tumo
pseudoglandular pattern was the tumor cells arranged as glandular structures
(lower panels), HE staining, 200×.Conclusions
The present study proves preliminarily that neonatal in-
oculation with HBV, consequently resulting in persistent
HBV infection, is capable of inducing HCC in tree shrews.
The tree shrew model could be a practical platform foreoplastic cells showed marked cellular pleomorphism. Multinucleated
, HE staining, 200× and 400× (insert) respectively. B. Morphological
rn was the tumor cells arranged in sheets with little intervening stroma
r cells arranged in short and irregular cords (lower left panel). The
(lower right panel). Tumor tissues of 98–2 (upper panels) and 121–1
Figure 5 HepPar-1 and CD31 immunohistochemistry. A. HepPar-1 in the liver tumor tissue. The neoplastic cells showed diffusely HepPar-1
positive. A tumor tissue of 121–1, immunohistochemical staining for HepPar-1, 200×. B. HepPar-1 in the normal liver tissue. Normal hepatocytes
generally showed HepPar-1 positive. A liver tissue of 131–3, immunohistochemical staining for HepPar-1, 200×. C. CD31 in the liver tumor tissue.
CD31 was densely stained along the membrane of the sinusoidal endothelial cells. A tumor tissue of 121–1, immunohistochemical staining for
CD31, 100×. D. CD31 in the normal liver tissue. Liver sinusoidal endothelial cells in the non-tumor tissue were CD31 negative, only blood vessels
in portal tracts were positive. A liver tissue of 137–2, immunohistochemical staining for CD31, 100×.
Figure 6 Ki67 immunohistochemistry. The density of Ki67-positive cells inside the live tumor (A) was much higher than that in the tumor-
surrounding tissue (B), the liver biopsies collected before occurrence of liver tumor (C) and the liver biopsies collected from animals in group B
(D). Immunohistochemical staining for Ki67, 100×.
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HCC 2 21.70 ± 6.65
Peri-HCC 2 10.00 ± 0.57 0.333
*Liver biopsies of
group A
6 8.93 ± 6.02 0.143
*Liver biopsies of
group B
9 5.27 ± 5.25 0.036
*Liver biopsies for Ki67 staining were collected around the 248th week after
inoculation from the animals in group A and B, respectively.
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well as the related therapeutic measures.
Materials and methods
Animal experiment
The study protocol was approved by the Ethical Commit-
tee of Guangxi Tumor Hospital in accordance with the
guidelines issued by Chinese government, which conforms
to the criteria outlined in the “Guide for the Care and Use
of Laboratory Animals” prepared by the National Acad-
emy of Sciences and published by the National Institutes
of Health (NIH publication no. 86–23 revised 1985).
The tree shrews used in this study were descended
from a population of wild tree shrews (Tupaia belangeri
chinensis) originating from the Kunming Institute of
Zoology, Chinese Academy of Science (Yunnan, China).
They were reared artificially since birth, housed at the
Laboratory Animal Center of Guangxi Medical Univer-
sity, and monitored by veterinarians.
All the tree shrews presented in this study were
followed-up from an experiment described in our previ-
ous reports [16,17], which 46 neonatal tree shrews were
inoculated with HBV-infected sera, and six tree shrews
were then diagnosed as having chronic HBV infection
since the presences of HBV-infection markers were longer
than 48 weeks after inoculation. These six chronically
HBV-infected tree shrews were grouped to A in this
study, while group B recruited nine tree shrews that were
confirmed as non-chronically HBV-infected by long-term
observation after HBV inoculation and served as controls.
The methods of HBV inoculation and sample collec-
tion were described previously [16,17]. Briefly, newborn
tree shrews were subcutaneously injected with HBV-
infected serum (HBsAg-, HBeAg- and HBcAb-positive,
HBV DNA ≥ 107 IU/ml) twice, 300 ~ 500 μl/animal each
time, on the first and third days after birth, respectively.
The HBV inoculum was either from human HBV-
carriers or from an infected tree shrew (90–1), all of
which were HBV genotype B [16]. Serum samples and
liver biopsies were collected periodically from each
animal after inoculation. Serum samples were used fortesting HBV-infection markers, while liver biopsies were
used for HBV DNA, histopathological and immunohis-
tochemical examinations.
Detection of HBV serological markers and HBV DNA in
serum and liver
All the methods of enzyme-linked immunoabsorbent
assay (ELISA), time-resolved immunofluorescence ana-
lysis (TRFIA) and fluorescence quantitative polymerase
chain reaction (FQ-PCR) for detecting HBV-infection
markers were carried out by the Clinical Laboratory
Center of Guangxi Tumor Hospital (Nanning, China).
The operations were conducted by using validated pro-
cedures for clinical specimens, and according to the
manufacturer’s instructions.
ELISA was applied to detect HBsAg, HBsAb, HBeAg,
HBeAb and HBcAb in serum, by using an automatic
processor ML-FAME (AusBio Company, Bonaduz,
Switzerland) and the commercial kits from Kehua Bio-
engineering Co. (Shanghai, China). The HBsAg-positive
specimens were then further analyzed quantitatively by
TRFIA, which was conducted on an automated im-
munoassay system Wallac AutoDELFIA (PerkinElmer
Co., Turku, Finland) with the commercial kits from
Xinbo Biotechnology Co. (Suzhou, China).
HBV DNA in serum and in liver biopsies was assessed
quantitatively by FQ-PCR. This assay was performed
on an analyzer Light Cycle® 480 II (Roche Diagnostics
GmbH., Mannheim, Germany) with the commercial kit
careHBV PCR ASSAY (QIAGEN Shenzhen Co., Ltd.,
Shenzhen, China). Before the FQ-PCR, liver DNA was
extracted by using a QIAamp DNA Blood Mini Kit
(Qiagen, Hilden, Germany) with a modified procedure
as our previously reports [16,17]. The results of FQ-PCR
were expressed as IU/ml in serum and as IU/μg liver
DNA in liver. The threshold applied to classifying a tree
shrew serum sample as positive was ≥5 × 102 IU/ml,
identical to the value recommended by the kit’s manu-
facturer for testing human samples. As no standard
method and critical threshold for FQ-PCR detecting
HBV DNA in liver tissues have been established so far,
we employed the cut-off value as >1 × 104 IU/μg liver
DNA, by referring the results from detecting the con-
trols from HBV-infected human and normal tree shrews.
Histopathological and immunochemical observation on
liver tissues
Hematoxylin and eosin (H&E) and immunohistochemi-
cal staining were performed on the paraffin-embedded
liver biopsies, all in accordance with conventional proce-
dures. The monoclonal antibodies of mouse anti-human
HBsAg, HBcAg, HepPar-1, CD31 and Ki67 were purchased
from Zhongshan Goldenbridge Biotech (Beijing, China).
Ki67 stained slices were analyzed quantitatively, based on
Yang et al. Virology Journal  (2015) 12:26 Page 10 of 10the reported method [20,21]. Briefly, 8–10 high-powered
fields (×400) were randomly selected for measuring about
500 hepatocytes per specimen. The nuclei-positive hepa-
tocytes were counted, and the results were expressed as
proportion (%) of positive cells.
Statistical analysis
Statistical analysis was conducted with SPSS 17.0 soft-
ware (IBM, Chicago, USA). Wilcoxon Test was applied
to compare the observation period of the two animal
groups (Table 1) and the proportions of Ki67-positive
hepatocytes in each comparable group (Table 4). The
significance level was P <0.05.
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